{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T03:36:48Z","timestamp":1782185808391,"version":"3.54.5"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11894-025-01026-x","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T11:36:29Z","timestamp":1763552189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associated Liver Disease"],"prefix":"10.1007","volume":"27","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Young","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Luther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"1026_CR1","unstructured":"Association AP. Diagnostic and statistical manual of mental Disorders, fifth Edition, text revision (DSM-5-TR). American Psychiatric Publishing; 2022."},{"key":"1026_CR2","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1016\/j.cgh.2022.11.033","volume":"21","author":"BS Hofer","year":"2023","unstructured":"Hofer BS, Simbrunner B, Hartl L, et al. Alcohol abstinence improves prognosis across all stages of portal hypertension in Alcohol-Related cirrhosis. Clin Gastroenterol Hepatol. 2023;21:2308\u201317. e7.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1026_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101162","volume":"29","author":"H Hern\u00e1ndez-\u00c9vole","year":"2024","unstructured":"Hern\u00e1ndez-\u00c9vole H, Jim\u00e9nez-Esquivel N, Pose E, et al. Alcohol-associated liver disease: epidemiology and management. Ann Hepatol. 2024;29:101162.","journal-title":"Ann Hepatol"},{"key":"1026_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41575-021-00527-0","volume":"19","author":"JP Arab","year":"2022","unstructured":"Arab JP, Izzy M, Leggio L, et al. Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation. Nat Rev Gastroenterol Hepatol. 2022;19:45\u201359.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1026_CR5","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1001\/jama.1988.03410170090040","volume":"260","author":"TE Starzl","year":"1988","unstructured":"Starzl TE, Van Thiel D, Tzakis AG, et al. Orthotopic liver transplantation for alcoholic cirrhosis. JAMA. 1988;260:2542\u20134.","journal-title":"JAMA"},{"key":"1026_CR6","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa1105703","volume":"365","author":"P Mathurin","year":"2011","unstructured":"Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365:1790\u2013800.","journal-title":"N Engl J Med"},{"key":"1026_CR7","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1016\/j.ajt.2025.01.022","volume":"25","author":"AJ Kwong","year":"2025","unstructured":"Kwong AJ, Kim WR, Lake JR, et al. OPTN\/SRTR 2023 annual data report: liver. Am J Transplant. 2025;25:S193\u2013287.","journal-title":"Am J Transplant"},{"key":"1026_CR8","doi-asserted-by":"crossref","unstructured":"Erard-Poinsot D, Dharancy S, Hilleret MN et al. Natural history of recurrent Alcohol\u2010Related cirrhosis after liver transplantation: fast and furious. Liver Transpl 2020;26.","DOI":"10.1002\/lt.25647"},{"key":"1026_CR9","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.2014.3628","volume":"311","author":"DE Jonas","year":"2014","unstructured":"Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311:1889\u2013900.","journal-title":"JAMA"},{"key":"1026_CR10","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","volume":"295","author":"RF Anton","year":"2006","unstructured":"Anton RF, O\u2019Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependencethe COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003\u201317.","journal-title":"JAMA"},{"key":"1026_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/MLR.0b013e3181d68859","volume":"48","author":"GA Zarkin","year":"2010","unstructured":"Zarkin GA, Bray JW, Aldridge A, et al. The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study. Med Care. 2010;48:396\u2013401.","journal-title":"Med Care"},{"key":"1026_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.3387","volume":"7","author":"EY Bernstein","year":"2024","unstructured":"Bernstein EY, Baggett TP, Trivedi S, et al. Outcomes after initiation of medications for alcohol use disorder at hospital discharge. JAMA Netw Open. 2024;7:e243387\u2013243387.","journal-title":"JAMA Netw Open"},{"key":"1026_CR13","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1002\/hep.31042","volume":"71","author":"S Rogal","year":"2020","unstructured":"Rogal S, Youk A, Zhang H, et al. Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis. Hepatology. 2020;71:2080\u201392.","journal-title":"Hepatology"},{"key":"1026_CR14","doi-asserted-by":"crossref","unstructured":"Rabiee A, Mahmud N, Falker C et al. Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis. Hepatol Commun 2023;7.","DOI":"10.1097\/HC9.0000000000000093"},{"key":"1026_CR15","unstructured":"Organization WH. Global status report on alcohol and health and treatment of substance use disorders. World Health Organization; 2024."},{"key":"1026_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3350\/cmh.2024.0835","volume":"31","author":"P Danpanichkul","year":"2025","unstructured":"Danpanichkul P, D\u00edaz LA, Suparan K, et al. Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000\u20132021. Clin Mol Hepatol. 2025;31:525\u201347.","journal-title":"Clin Mol Hepatol"},{"key":"1026_CR17","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1016\/j.cgh.2023.02.017","volume":"21","author":"JP Arab","year":"2023","unstructured":"Arab JP, Addolorato G, Mathurin P, et al. Alcohol-associated liver disease: integrated management with alcohol use disorder. Clin Gastroenterol Hepatol. 2023;21:2124\u201334.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1026_CR18","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1172\/JCI105200","volume":"44","author":"CS Lieber","year":"1965","unstructured":"Lieber CS, Jones DP, DeCarli LM. Effects of prolonged ethanol intake: production of fatty liver despite adequate diets. J Clin Invest. 1965;44:1009\u201321.","journal-title":"J Clin Invest"},{"key":"1026_CR19","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3350\/cmh.2020.0142","volume":"26","author":"T Miyata","year":"2020","unstructured":"Miyata T, Nagy LE. Programmed cell death in alcohol-associated liver disease. Clin Mol Hepatol. 2020;26:618\u201325.","journal-title":"Clin Mol Hepatol"},{"key":"1026_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/hep.30866","volume":"71","author":"DW Crabb","year":"2020","unstructured":"Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of Alcohol-Associated liver diseases: 2019 practice guidance from the American association for the study of liver diseases. Hepatology. 2020;71:306\u201333.","journal-title":"Hepatology"},{"key":"1026_CR21","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1056\/NEJMra1715733","volume":"379","author":"D Fuster","year":"2018","unstructured":"Fuster D, Samet JH. Alcohol use in patients with chronic liver disease. N Engl J Med. 2018;379:1251\u201361.","journal-title":"N Engl J Med"},{"key":"1026_CR22","doi-asserted-by":"publisher","first-page":"879","DOI":"10.7326\/M23-0518","volume":"176","author":"BP Lee","year":"2023","unstructured":"Lee BP, Dodge JL, Mack WJ, et al. National trends in alcohol use, metabolic syndrome, and liver disease from 1999 to 2018. Ann Intern Med. 2023;176:879\u201382.","journal-title":"Ann Intern Med"},{"key":"1026_CR23","unstructured":"SAMHSA C. 2023 National Survey on Drug Use and Health. Table 5.21B \u2013 Received medication-assisted treatment (MAT) for alcohol use in past year: among people aged 12 and older; received MAT for alcohol use in past year: among people aged 12 and older with past year alcohol use disorder; by demographic characteristics, percentages, 2022 and 2023, 2023."},{"key":"1026_CR24","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.7326\/M23-0641","volume":"176","author":"EY Bernstein","year":"2023","unstructured":"Bernstein EY, Baggett TP, Trivedi S, et al. Pharmacologic treatment initiation among Medicare beneficiaries hospitalized with alcohol use disorder. Ann Intern Med. 2023;176:1137\u20139.","journal-title":"Ann Intern Med"},{"key":"1026_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/acer.13944","volume":"43","author":"JL Mellinger","year":"2019","unstructured":"Mellinger JL, Fernandez A, Shedden K, et al. Gender disparities in alcohol use disorder treatment among privately insured patients with alcohol-associated cirrhosis. Alcohol Clin Exp Res. 2019;43:334\u201341.","journal-title":"Alcohol Clin Exp Res"},{"key":"1026_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000145","volume":"7","author":"JL Mellinger","year":"2023","unstructured":"Mellinger JL, Fernandez AC, Winder GS. Management of alcohol use disorder in patients with chronic liver disease. Hepatol Commun. 2023;7:e00145.","journal-title":"Hepatol Commun"},{"key":"1026_CR27","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1016\/j.cgh.2020.10.026","volume":"19","author":"GY Im","year":"2021","unstructured":"Im GY, Mellinger JL, Winters A, et al. Provider attitudes and practices for alcohol Screening, Treatment, and education in patients with liver disease: A survey from the American association for the study of liver diseases alcohol-Associated liver disease special interest group. Clin Gastroenterol Hepatol. 2021;19:2407\u2013e24168.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1026_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.55320","volume":"7","author":"R Mahle","year":"2024","unstructured":"Mahle R, Okanlawon A, Luther J, et al. Stigmatizing language for alcohol use disorder and liver disease on liver transplant center websites. JAMA Netw Open. 2024;7:e2355320.","journal-title":"JAMA Netw Open"},{"key":"1026_CR29","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.drugpo.2009.10.010","volume":"21","author":"JF Kelly","year":"2010","unstructured":"Kelly JF, Westerhoff CM. Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. Int J Drug Policy. 2010;21:202\u20137.","journal-title":"Int J Drug Policy"},{"key":"1026_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","volume":"175","author":"VI Reus","year":"2018","unstructured":"Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175:86\u201390.","journal-title":"Am J Psychiatry"},{"key":"1026_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/bcp.12070","volume":"77","author":"NJ Kalk","year":"2014","unstructured":"Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. Br J Clin Pharmacol. 2014;77:315\u201323.","journal-title":"Br J Clin Pharmacol"},{"key":"1026_CR32","first-page":"1","volume":"6","author":"SL Yahn","year":"2013","unstructured":"Yahn SL, Watterson LR, Olive MF. Safety and efficacy of acamprosate for the treatment of alcohol dependence. Subst Abuse. 2013;6:1\u201312.","journal-title":"Subst Abuse"},{"key":"1026_CR33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/MEG.0000000000002304","volume":"34","author":"LD Tyson","year":"2022","unstructured":"Tyson LD, Cheng A, Kelleher C, et al. Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice. Eur J Gastroenterol Hepatol. 2022;34:567\u201375.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1026_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.14309\/ajg.0000000000002572","volume":"119","author":"LL Jophlin","year":"2024","unstructured":"Jophlin LL, Singal AK, Bataller R, et al. ACG clinical guideline: alcohol-associated liver disease. Am J Gastroenterol. 2024;119:30\u201354.","journal-title":"Am J Gastroenterol"},{"key":"1026_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.12.009","author":"SY Hwang","year":"2025","unstructured":"Hwang SY, Luther J, Zhang W. Gastrointestinal and liver adverse effects of alcohol use disorder medications: a pharmacovigilance analysis. Clin Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2024.12.009.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1026_CR36","unstructured":"[Internet] LCRID-ILI, Disulfiram. Volume. 2025. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012-."},{"key":"1026_CR37","doi-asserted-by":"crossref","unstructured":"Roesner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane database of systematic reviews; 2010.","DOI":"10.1002\/14651858.CD001867.pub3"},{"key":"1026_CR38","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0168-8278(97)80355-8","volume":"27","author":"M Bertolotti","year":"1997","unstructured":"Bertolotti M, Ferrari A, Vitale G, et al. Effect of liver cirrhosis on the systemic availability of Naltrexone in humans. J Hepatol. 1997;27:505\u201311.","journal-title":"J Hepatol"},{"key":"1026_CR39","unstructured":"Naltrexone for extended. -release injectable suspension (marketed as Vivitrol) Information | FDA."},{"key":"1026_CR40","doi-asserted-by":"publisher","first-page":"112789","DOI":"10.1016\/j.drugalcdep.2025.112789","volume":"274","author":"A Elmosalamy","year":"2025","unstructured":"Elmosalamy A, Sirohi A, Moustafa A, et al. Extended-release Naltrexone versus oral Naltrexone for substance use disorders: A systematic review and meta-analysis. Drug Alcohol Depend. 2025;274:112789.","journal-title":"Drug Alcohol Depend"},{"key":"1026_CR41","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamainternmed.2025.0522","volume":"185","author":"KM Magane","year":"2025","unstructured":"Magane KM, Dukes KA, Fielman S, et al. Oral vs extended-release injectable naltrexone for hospitalized patients with alcohol use disorder: a randomized clinical trial. JAMA Intern Med. 2025;185:635\u201345.","journal-title":"JAMA Intern Med"},{"key":"1026_CR42","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.cgh.2024.12.009","volume":"23","author":"SY Hwang","year":"2025","unstructured":"Hwang SY, Luther J, Zhang W. Gastrointestinal and liver adverse effects of alcohol use disorder medications: A pharmacovigilance analysis. Clin Gastroenterol Hepatol. 2025;23:1458\u2013e14608.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1026_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101095","author":"R Thompson","year":"2024","unstructured":"Thompson R, Taddei T, Kaplan D, et al. Safety of naltrexone in patients with cirrhosis. JHEP Reports. 2024. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101095.","journal-title":"JHEP Reports"},{"key":"1026_CR44","doi-asserted-by":"crossref","unstructured":"Diaz LA, Collier S, Yin J, et al. Safety and tolerability of injectable Extended-Release Naltrexone for the management of alcohol use disorder in advanced alcohol-Associated liver disease. Aliment Pharmacol Ther; 2025.","DOI":"10.1111\/apt.70237"},{"key":"1026_CR45","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/MEG.0000000000000922","volume":"29","author":"C Barrault","year":"2017","unstructured":"Barrault C, Lison H, Roudot-Thoraval F, et al. One year of Baclofen in 100 patients with or without cirrhosis: a French real-life experience. Eur J Gastroenterol Hepatol. 2017;29:1155\u201360.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1026_CR46","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","volume":"370","author":"G Addolorato","year":"2007","unstructured":"Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370:1915\u201322.","journal-title":"Lancet"},{"key":"1026_CR47","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.3389\/fpsyt.2018.00708","volume":"9","author":"R de Beaurepaire","year":"2019","unstructured":"de Beaurepaire R, Sinclair JMA, Heydtmann M, et al. The use of Baclofen as a treatment for alcohol use disorder: A clinical practice perspective. Front Psychiatry. 2019;9:2018.","journal-title":"Front Psychiatry"},{"key":"1026_CR48","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/alcalc\/agx030","volume":"52","author":"M Reynaud","year":"2017","unstructured":"Reynaud M, Aubin HJ, Trinquet F, et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients-the ALPADIR study. Alcohol Alcohol. 2017;52:439\u201346.","journal-title":"Alcohol Alcohol"},{"key":"1026_CR49","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jamainternmed.2013.11950","volume":"174","author":"BJ Mason","year":"2014","unstructured":"Mason BJ, Quello S, Goodell V, et al. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014;174:70\u20137.","journal-title":"JAMA Intern Med"},{"key":"1026_CR50","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/13543784.2018.1417383","volume":"27","author":"BJ Mason","year":"2018","unstructured":"Mason BJ, Quello S, Shadan F. Gabapentin for the treatment of alcohol use disorder. Expert Opin Investig Drugs. 2018;27:113\u201324.","journal-title":"Expert Opin Investig Drugs"},{"key":"1026_CR51","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamainternmed.2020.0249","volume":"180","author":"RF Anton","year":"2020","unstructured":"Anton RF, Latham P, Voronin K, et al. Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial. JAMA Intern Med. 2020;180:728\u201336.","journal-title":"JAMA Intern Med"},{"key":"1026_CR52","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/add.14655","volume":"114","author":"HR Kranzler","year":"2019","unstructured":"Kranzler HR, Feinn R, Morris P, et al. A meta-analysis of the efficacy of Gabapentin for treating alcohol use disorder. Addiction. 2019;114:1547\u201355.","journal-title":"Addiction"},{"key":"1026_CR53","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1212\/WNL.67.12_suppl_4.S28","volume":"67","author":"G Lacerda","year":"2006","unstructured":"Lacerda G, Krummel T, Sabourdy C, et al. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology. 2006;67:S28-33.","journal-title":"Neurology"},{"key":"1026_CR54","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/acer.12411","volume":"38","author":"JC Blodgett","year":"2014","unstructured":"Blodgett JC, Del Re AC, Maisel NC, et al. A meta-analysis of topiramate\u2019s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014;38:1481\u20138.","journal-title":"Alcohol Clin Exp Res"},{"key":"1026_CR55","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","volume":"361","author":"BA Johnson","year":"2003","unstructured":"Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677\u201385.","journal-title":"Lancet"},{"issue":"5","key":"1026_CR56","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/CLD.0000000000000033","volume":"21","author":"C Coe","year":"2023","unstructured":"Coe C, Patel A, Lawrence D. Pharmacotherapy options for alcohol use disorder in patients with alcohol-associated liver disease: a brief guide for clinicians. Clin Liver Dis. 2023;21(5):125\u20139.","journal-title":"Clin Liver Dis"},{"key":"1026_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48780-6","volume":"15","author":"W Wang","year":"2024","unstructured":"Wang W, Volkow ND, Berger NA, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun. 2024;15:4548.","journal-title":"Nat Commun"},{"key":"1026_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48267-2","volume":"13","author":"F Quddos","year":"2023","unstructured":"Quddos F, Hubshman Z, Tegge A, et al. Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep. 2023;13:20998.","journal-title":"Sci Rep"},{"key":"1026_CR59","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","volume":"82","author":"CS Hendershot","year":"2025","unstructured":"Hendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatr. 2025;82:395\u2013405.","journal-title":"JAMA Psychiatr"},{"key":"1026_CR60","doi-asserted-by":"publisher","first-page":"4812","DOI":"10.1523\/JNEUROSCI.6326-11.2012","volume":"32","author":"SL Dickson","year":"2012","unstructured":"Dickson SL, Shirazi RH, Hansson C, et al. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J Neurosci. 2012;32:4812\u201320.","journal-title":"J Neurosci"},{"key":"1026_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104642","volume":"93","author":"C Aran\u00e4s","year":"2023","unstructured":"Aran\u00e4s C, Edvardsson CE, Shevchouk OT, et al. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine. 2023;93:104642.","journal-title":"EBioMedicine"},{"key":"1026_CR62","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/apt.70007","volume":"61","author":"C-C Kuo","year":"2025","unstructured":"Kuo C-C, Li C-H, Chuang M-H, et al. Impact of GLP-1 receptor agonists on alcohol-related liver disease development and progression in alcohol use disorder. Aliment Pharmacol Ther. 2025;61:1343\u201356.","journal-title":"Aliment Pharmacol Ther"},{"key":"1026_CR63","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S2468-1253(25)00134-7","volume":"10","author":"AK Singal","year":"2025","unstructured":"Singal AK, Leggio L. GLP-1 receptor agonists in alcohol use disorder and alcohol-associated liver disease. Lancet Gastroenterol Hepatol. 2025;10:707\u20139.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1026_CR64","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following Psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatr. 2022;79:953\u201362.","journal-title":"JAMA Psychiatr"},{"key":"1026_CR65","volume":"82","author":"NM Rieser","year":"2025","unstructured":"Rieser NM, Bitar R, Halm S, et al. Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial. E Clin Med. 2025;82:103149.","journal-title":"E Clin Med"},{"key":"1026_CR66","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cmet.2021.12.024","volume":"34","author":"KH Flippo","year":"2022","unstructured":"Flippo KH, Trammell SAJ, Gillum MP, et al. FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit. Cell Metab. 2022;34:317\u201328. e6.","journal-title":"Cell Metab"},{"key":"1026_CR67","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.molmet.2017.08.004","volume":"6","author":"BN Desai","year":"2017","unstructured":"Desai BN, Singhal G, Watanabe M, et al. Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury. Mol Metab. 2017;6:1395\u2013406.","journal-title":"Mol Metab"},{"key":"1026_CR68","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1113\/JP277117","volume":"597","author":"S von Holstein-Rathlou","year":"2019","unstructured":"von Holstein-Rathlou S, Gillum MP. Fibroblast growth factor 21: an endocrine inhibitor of sugar and alcohol appetite. J Physiol. 2019;597:3539\u201348.","journal-title":"J Physiol"},{"key":"1026_CR69","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.molmet.2018.03.010","volume":"11","author":"S Soberg","year":"2018","unstructured":"Soberg S, Andersen ES, Dalsgaard NB, et al. FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at oktoberfest. Mol Metab. 2018;11:96\u2013103.","journal-title":"Mol Metab"},{"key":"1026_CR70","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.alcohol.2024.08.001","volume":"121","author":"AR Lanng","year":"2024","unstructured":"Lanng AR, Gasbjerg LS, Sucksdorff AIF, et al. Alcohol-induced fibroblast growth factor 21 secretion is increased in individuals with alcohol use disorder. Alcohol. 2024;121:69\u201374.","journal-title":"Alcohol"},{"key":"1026_CR71","doi-asserted-by":"crossref","unstructured":"Cooley BJ, Occelli Hanbury-Brown CV, Choi EA et al. FGF21 analogue PF-05231023 on alcohol consumption and neuronal activity in the nucleus accumbens. Neuropsychopharmacology. 2025.","DOI":"10.1101\/2024.12.22.629996"},{"key":"1026_CR72","doi-asserted-by":"crossref","unstructured":"Boutari C, Triantafyllou A, Papalavrentios L et al. FGF21 analogues and MASLD: A summary of preclinical and clinical data. Curr Pharm Des 2025.","DOI":"10.2174\/0113816128374854250709050425"},{"key":"1026_CR73","unstructured":"Effects of NNC0194-0499. Cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-related Liver Disease | ClinicalTrials.gov."},{"key":"1026_CR74","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.13014","volume":"5","author":"AGL Vannier","year":"2022","unstructured":"Vannier AGL, Shay JES, Fomin V, et al. Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder. JAMA Netw Open. 2022;5:e2213014.","journal-title":"JAMA Netw Open"},{"key":"1026_CR75","doi-asserted-by":"crossref","unstructured":"Singal AK, Zhang W, Shetty A et al. Treatment of alcohol use disorder in alcohol-associated liver disease: A meta-analysis. Hepatol Commun 2025;9.","DOI":"10.1097\/HC9.0000000000000686"},{"key":"1026_CR76","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.cld.2021.03.008","volume":"25","author":"PS Ting","year":"2021","unstructured":"Ting PS, Gurakar A, Wheatley J, et al. Approaching alcohol use disorder after liver transplantation for acute alcoholic hepatitis. Clin Liver Dis. 2021;25:645\u201371.","journal-title":"Clin Liver Dis"},{"key":"1026_CR77","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/LVT.0000000000000475","volume":"31","author":"D Ayyala-Somayajula","year":"2025","unstructured":"Ayyala-Somayajula D, Bottyan T, Shaikh S, et al. Safety of acamprosate for alcohol use disorder after liver transplant: a pilot randomized controlled trial. Liver Transpl. 2025;31:498\u2013507.","journal-title":"Liver Transpl"},{"key":"1026_CR78","unstructured":"IM Naltrexone Post Liver Transplant for Alcoholic Hepatitis. Patients to Prevent Relapse - ATC Abstracts."},{"key":"1026_CR79","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1056\/NEJMra2306511","volume":"392","author":"PS Haber","year":"2025","unstructured":"Haber PS. Identification and treatment of alcohol use disorder. N Engl J Med. 2025;392:258\u201366.","journal-title":"N Engl J Med"},{"key":"1026_CR80","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.8279","volume":"3","author":"LA Ray","year":"2020","unstructured":"Ray LA, Meredith LR, Kiluk BD, et al. Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: a systematic review and meta-analysis. JAMA Netw Open. 2020;3:e208279.","journal-title":"JAMA Netw Open"},{"key":"1026_CR81","doi-asserted-by":"crossref","unstructured":"Mellinger JL, Medley S, Kidwell KM et al. Improving alcohol treatment engagement using integrated behavioral interventions in alcohol-associated liver disease: A randomized pilot trial. Hepatol Commun 2023;7.","DOI":"10.1097\/HC9.0000000000000181"},{"key":"1026_CR82","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jaclp.2021.07.012","volume":"63","author":"J Whitfield","year":"2022","unstructured":"Whitfield J, LePoire E, Stanczyk B, et al. Remote collaborative care with off-site behavioral health care managers: a systematic review of clinical trials. Journal of the Academy of Consultation-Liaison Psychiatry. 2022;63:71\u201385.","journal-title":"Journal of the Academy of Consultation-Liaison Psychiatry"},{"key":"1026_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.07.019","author":"N Torp","year":"2025","unstructured":"Torp N, Israelsen M, Thiele M, et al. Phosphatidylethanol in steatotic liver disease. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.07.019.","journal-title":"J Hepatol"},{"key":"1026_CR84","doi-asserted-by":"crossref","unstructured":"Sengupta S, Anand A, Yang Q et al. The impact of integrated care on clinical outcomes in patients with alcohol-associated liver disease: early outcomes from a multidisciplinary clinic. Hepatol Commun 2025;9.","DOI":"10.1097\/HC9.0000000000000603"},{"issue":"6","key":"1026_CR85","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.cgh.2022.03.042","volume":"21","author":"V Fomin","year":"2023","unstructured":"Fomin V, Marshall C, Tsai S, et al. Creation of an inpatient alcohol liver service improves early liver disease detection in patients with alcohol use disorder. Clin Gastroenterol Hepatol. 2023;21(6):1646\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1026_CR86","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S2468-1253(21)00191-6","volume":"7","author":"AF DiMartini","year":"2022","unstructured":"DiMartini AF, Leggio L, Singal AK. Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models. Lancet Gastroenterol Hepatol. 2022;7:186\u201395.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1026_CR87","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1016\/j.cgh.2020.10.026","volume":"19","author":"GY Im","year":"2021","unstructured":"Im GY, Mellinger JL, Winters A, et al. Provider attitudes and practices for alcohol Screening, Treatment, and education in patients with liver disease: A survey from the American association for the study of liver diseases alcohol-Associated liver disease special interest group. Clin Gastroenterol Hepatol. 2021;19:2407\u201316. e8.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1026_CR88","volume-title":"Incorporating alcohol pharmacotherapies into medical Practice. Chapter 2\u2014Acamprosate","author":"Treatment CfSA","year":"2009","unstructured":"Treatment CfSA. Incorporating alcohol pharmacotherapies into medical Practice. Chapter 2\u2014Acamprosate. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2009."},{"key":"1026_CR89","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000443","author":"A Manhapra","year":"2019","unstructured":"Manhapra A, Chakraborty A, Arias AJ. Topiramate pharmacotherapy for alcohol use disorder and other addictions: a narrative review. J Addict Med. 2019. https:\/\/doi.org\/10.1097\/ADM.0000000000000443","journal-title":"J Addict Med"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-025-01026-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-025-01026-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-025-01026-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:02:24Z","timestamp":1772578944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11894-025-01026-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1026"],"URL":"https:\/\/doi.org\/10.1007\/s11894-025-01026-x","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}